10 Oversold Global Stocks To Buy Right Now

6. Silence Therapeutics plc (NASDAQ:SLN)

14-day RSI Score: 26.93

Number of Hedge Fund Investors In Q3 2024: 25

Silence Therapeutics plc (NASDAQ:SLN) is a British biotechnology company. The firm develops genetically engineered medicines to target a variety of ailments such as blood cancer, liver diseases, kidney problems, and others. Silence Therapeutics plc (NASDAQ:SLN)’s shares have lost a whopping 60% year-to-date, with the losses driven by a sizable 60% dip in November prior to which the stock had lost 5.4% year-to-date. The sell-off started after Silence Therapeutics plc (NASDAQ:SLN)’s third-quarter results which saw its quarterly revenue drop by 59%, R&D expenses and operating expenses jump by 72% and 10.7%, and the net loss widen by 230% in an all-round set of weak results.  The share price drop came even though while its shares were dropping, Silence Therapeutics plc (NASDAQ:SLN)’s data for its zerlasiran drug led to an up to 90% reduction in lipoproteins that are responsible for heart disease. Looking ahead, zerlasiran making it to phase two, and the firm’s blood cancer drug advancing in the trial phases can drive the stock forward.